TY  - JOUR
AU  - Petykó, Zsuzsanna Ida
AU  - Kaló, Zoltán
AU  - Espin, Jaime
AU  - Podrazilová, Kateřina
AU  - Tesař, Tomáš
AU  - Maniadakis, Nikos
AU  - Fricke, Frank-Ulrich
AU  - Inotai, András
PY  - 2021
DO  - 10.1186/s12962-021-00311-6
SN  - 1478-7547
UR  - http://hdl.handle.net/10668/18485
T2  - Cost effectiveness and resource allocation : C/E
AB  - Medicines that are based on known molecules and are further developed to address healthcare needs and deliver relevant improvement for patients, healthcare professionals and/or payers are called value-added medicines (VAMs). The evaluation process of...
LA  - en
KW  - Expert panel
KW  - Generic price erosion
KW  - Incremental innovation
KW  - Repurposed medicine
KW  - Value assessment framework
KW  - Value domain
KW  - Value proposition
KW  - Value-added medicines
TI  - Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings.
TY  - research article
VL  - 19
ER  -